Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
DVL3
REST API REST API
Homo sapiens
DVL3 is differentially expressed in 272 experiments: 140 organism parts: placenta, bone marrow, ... (138 more);, 212 disease states: normal, control, ... (210 more);, 91 cell types 366 cell lines 33 compound treatments and 76 other conditions.
Synonyms KIAA0208
Orthologs Q9NL46_CIOIN (Ciona intestinalis)   DVL3 (Gallus gallus)   dvl3 (Danio rerio)   Dvl3 (Rattus norvegicus)   DVL3 (1 of 2) (Danio rerio)   Dvl3 (Mus musculus)   DVL3 (Bos taurus)   dsh (Drosophila melanogaster)   dvl3 (Xenopus laevis)   DVL3 (Canis familiaris)   (Compare orthologs)
InterPro Term Dishevelled_1, Dishevelled, DEP_dom, PDZ/DHR/GLGF, DIX, Dishevelled_3, Dishevelled_C-dom, Dishevelled_protein_dom
Gene Ontology Term frizzled binding, protein binding, cytoplasm, beta-catenin binding, intracellular, cell cortex, Wnt receptor signaling pathway, planar cell polarity pathway, receptor binding, positive regulation of JUN kinase activity, signal transducer activity, Wnt receptor signaling pathway, multicellular organismal development, protein heterodimerization activity, canonical Wnt receptor signaling pathway, response to drug, positive regulation of transcription, DNA-dependent, protease binding, non-canonical Wnt receptor signaling pathway, outflow tract septum morphogenesis, cochlea morphogenesis, convergent extension, intracellular signal transduction, positive regulation of protein phosphorylation, planar cell polarity pathway involved in neural tube closure
UniProt Accession Q8WVA8, Q92997, C9K0P9, B4E3E5, F5GWR8, F8WCF1
Search EB-eye ENSG00000161202
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (35 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
SW480
2
E-MTAB-37, E-GEOD-18005
A549
2
E-GEOD-3202, E-GEOD-6013
MCF-10A
2
E-TABM-420, E-GEOD-14990
MDA468
2
E-MEXP-440, E-MTAB-62
MDAMB453
2
E-MTAB-37, E-MTAB-62
360 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (47 experiments)

Factor Value U/D Experiments
plasma cell
2
E-GEOD-6691, E-MEXP-2360
embryonic stem cell
2
E-GEOD-2248, E-MEXP-930
mononuclear
2
E-GEOD-13987, E-GEOD-26672
CD11c+ dendritic cell
1
1
E-MEXP-1600
hematopoietic progenitor cells
1
E-MEXP-70
adipocyte
1
E-MTAB-25
85 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MEXP-1121, E-GEOD-16363, ... (58 experiments)

Factor Value U/D Experiments
prostate carcinoma
2
E-MTAB-62, E-MEXP-1327
head and neck squamous cell carcinoma
2
E-MTAB-62, E-GEOD-2379
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
colon carcinoma
2
E-MTAB-62, E-MTAB-37
glioblastoma
2
E-GEOD-4290, E-MTAB-62
neuroblastoma
2
E-MTAB-37, E-MTAB-62
206 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, E-TABM-782, ... (23 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-MEXP-1958, E-TABM-868, E-GEOD-3720
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
chloroguine
1
E-GEOD-5418
bis [(+)-tartrato] diantimonate (III) dipotassium trihydrate
1
E-GEOD-6907
interferon-gamma + lipopolysaccharide
1
E-GEOD-5099
unknown
1
E-GEOD-7307
27 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21374, E-GEOD-4619, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, ... (6 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-17476, E-GEOD-22593, E-GEOD-18736, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-TABM-127, E-MEXP-1446, E-GEOD-10315, E-GEOD-837, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-TABM-15, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-9723, E-GEOD-17400

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-6434, E-GEOD-1657, E-GEOD-2487, ... (6 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.275 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM